Medicus Pharma Files FDA Rare Pediatric Disease Designation Request for SkinJect in Gorlin Syndrome

A layered regulatory incentive strategy is taking shape at Medicus Pharma, where a freshly filed Rare Pediatric Disease Designation (RPDD) request for SkinJect adds a third FDA pathway instrument to a program already carrying Orphan Drug Designation and a registrational study design under agency review. For regulatory affairs leads tracking rare disease precedents, the architecture of this submission is as instructive as the asset itself.

SkinJect is a dissolvable microneedle array that delivers doxorubicin (D-MNA) intradermally, targeting nodular basal cell carcinoma lesions directly while limiting systemic exposure. The RPDD filing, made under Section 529 of the Federal Food, Drug, and Cosmetic Act, covers the treatment of basal cell carcinoma in patients with Gorlin Syndrome, a rare autosomal dominant disorder driven by Hedgehog signaling pathway mutations. Affected individuals can develop hundreds to more than one thousand basal cell carcinomas across a lifetime, with lesions frequently appearing in childhood. The estimated U.S. patient population sits between 6,000 and 12,000.

The Phase 2 data underpinning the submission are drawn from the 200 mcg D-MNA treatment arm, which recorded 64% clinical clearance and 55% complete response among evaluable nodular BCC patients, alongside a favorable tolerability profile. Those figures now anchor both the ODD application (DRU-2026-11578) and the registrational study design SKNJCT-005, which remains under FDA review. Program design was informed by engagement with clinical experts and the Gorlin Syndrome Alliance.

The strategic value of RPDD eligibility extends beyond designation itself. If the designation is granted and a marketing application subsequently receives FDA approval for the indicated use, the program would become eligible for a Rare Pediatric Disease Priority Review Voucher, a transferable instrument with independent commercial value that small biotechs routinely factor into development economics. QA and regulatory teams at similarly positioned sponsors will note how Medicus has sequenced ODD, RPDD, and registrational study alignment before Phase 3 initiation, compressing the incentive-stacking timeline.

The next measurable checkpoint is FDA's response to the registrational study design SKNJCT-005, which will determine the confirmatory trial parameters Medicus must satisfy before any marketing application can be filed.

Source: Medicus Pharma via GlobeNewswire, June 15, 2026.